A phase III study of ABM-125 as a prophylactic treatment in poorly controlled asthmatics susceptible to exacerbations
Latest Information Update: 23 May 2017
Price :
$35 *
At a glance
- Drugs LNR 125.38 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 23 May 2017 New trial record